Please Wait
Applying Filters...
menu
    • menu
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Bezisterim

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    BioVie Hosts Live Investor Webinar on June 2
    BioVie Hosts Live Investor Webinar on June 2

    27 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/27/3301871/0/en/join-biovie-s-exclusive-live-investor-webinar-and-q-and-a-session-on-june-2.html

    GLOBENEWSWIRE
    27 May 2026
    Share Share
    BioVie Fully Enrolls Long COVID Neurology Trial of Bezisterim
    BioVie Fully Enrolls Long COVID Neurology Trial of Bezisterim

    26 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/26/3300996/0/en/biovie-announces-full-enrollment-of-the-address-lc-trial-of-bezisterim-for-the-treatment-of-neurological-symptoms-associated-with-long-covid.html

    GLOBENEWSWIRE
    26 May 2026
    Share Share
    BioVie Completes Phase 2 SUNRISE-PD Trial in Early Parkinson
    BioVie Completes Phase 2 SUNRISE-PD Trial in Early Parkinson

    18 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/18/3296537/0/en/biovie-announces-completion-of-phase-2-sunrise-pd-trial-in-early-stage-parkinson-s-disease.html

    GLOBENEWSWIRE
    18 May 2026
    Share Share
    BioVie Hosts Virtual KOL Event On Bezisterim Phase 2 Study
    BioVie Hosts Virtual KOL Event On Bezisterim Phase 2 Study

    27 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/27/3281541/0/en/biovie-to-host-virtual-kol-event-to-discuss-the-phase-2-study-of-bezisterim-for-the-treatment-of-parkinson-s-disease-ahead-of-topline-data-in-2q26-on-may-7-2026.html

    GLOBENEWSWIRE
    27 Apr 2026
    Share Share
    Biovie To Present Abstract At 2026 Aan Annual Meeting
    Biovie To Present Abstract At 2026 Aan Annual Meeting

    14 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/14/3273252/0/en/BioVie-Announces-Abstract-Accepted-for-Presentation-at-the-2026-American-Academy-of-Neurology-Annual-Meeting.html

    GLOBENEWSWIRE
    14 Apr 2026
    Share Share
    Biovie Announces Abstract Accepted For Presentation At AD/PD 2026
    Biovie Announces Abstract Accepted For Presentation At AD/PD 2026

    12 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/12/3254576/0/en/BioVie-Announces-Abstract-Accepted-for-Presentation-at-AD-PD-2026.html

    GLOBENEWSWIRE
    12 Mar 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.